Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

~48 mi. (Oklahoma City, Oklahoma, +523 more cities)

Mercy Hospital Oklahoma City, +1 more facility

Clear Cell Renal Cell Carcinoma

cabozantinib, +2 more drugs

immunotherapy, +1 more type

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

~48 mi. (Oklahoma City, Oklahoma, +576 more cities)

University of Oklahoma Health Sciences Center

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

ado-trastuzumab emtansine, +1 more drug

targeted therapy

Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy

~48 mi. (Oklahoma City, Oklahoma, +744 more cities)

Mercy Hospital Oklahoma City, +2 more facilities

Breast Carcinoma

axillary lymph node dissection, +1 more drug

radiation therapy, +1 more type

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

~48 mi. (Oklahoma City, Oklahoma, +269 more cities)

University of Oklahoma Health Sciences Center

ER Positive, +1 more biomarker

Invasive Breast Carcinoma

radiation therapy, +1 more drug

radiation therapy

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

~48 mi. (Oklahoma City, Oklahoma, +454 more cities)

University of Oklahoma Health Sciences Center

Classical Hodgkin Lymphoma

brentuximab vedotin, +7 more drugs

chemotherapy, +3 more types

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

~48 mi. (Oklahoma City, Oklahoma, +173 more cities)

University of Oklahoma Health Sciences Center

B-Cell Lymphoblastic Leukemia/Lymphoma

asparaginase Erwinia chrysanthemi, +12 more drugs

chemotherapy, +2 more types

Sasanlimab (PF-06801591) in Combination With BCG or as Single Agent in Participants With High-Risk Non-Muscle Invasive Bladder Cancer

~48 mi. (Oklahoma City, Oklahoma, +153 more cities)

OU Medical Center, +1 more facility

Bladder Urothelial Carcinoma, +2 more conditions

BCG solution, +1 more drug

immunotherapy

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

~48 mi. (Oklahoma City, Oklahoma, +140 more cities)

Stephenson Cancer Center ( Site 0745)

Hepatocellular Carcinoma

lenvatinib, +2 more drugs

chemotherapy, +2 more types

A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy

~48 mi. (Oklahoma City, Oklahoma, +233 more cities)

University of Oklahoma Health Sciences Center

Prostate Adenocarcinoma

degarelix, +4 more drugs

hormone therapy, +1 more type

Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy

~48 mi. (Oklahoma City, Oklahoma, +244 more cities)

Mercy Hospital Oklahoma City, +1 more facility

Bladder Urothelial Carcinoma, +4 more conditions

atezolizumab, +4 more drugs

immunotherapy

A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

~48 mi. (Oklahoma City, Oklahoma, +196 more cities)

Oklahoma City VAMC

Prostate Adenocarcinoma

anti-androgen therapy, +1 more drug

hormone therapy

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

~48 mi. (Oklahoma City, Oklahoma, +127 more cities)

University of Oklahoma Health Sciences Center, OU Health Stephenson Cancer Center

BRAF V600E

Colorectal Carcinoma

cetuximab, +3 more drugs

chemotherapy, +1 more type